HomeCompareBNPJY vs ABBV

BNPJY vs ABBV: Dividend Comparison 2026

BNPJY yields 6.37% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BNPJY wins by $25105.75M in total portfolio value
10 years
BNPJY
BNPJY
● Live price
6.37%
Share price
$1.60
Annual div
$0.10
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25105.85M
Annual income
$24,370,393,261.15
Full BNPJY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BNPJY vs ABBV

📍 BNPJY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBNPJYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BNPJY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BNPJY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BNPJY
Annual income on $10K today (after 15% tax)
$541.08/yr
After 10yr DRIP, annual income (after tax)
$20,714,834,271.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BNPJY beats the other by $20,714,813,215.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BNPJY + ABBV for your $10,000?

BNPJY: 50%ABBV: 50%
100% ABBV50/50100% BNPJY
Portfolio after 10yr
$12552.98M
Annual income
$12,185,209,016.45/yr
Blended yield
97.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BNPJY
No analyst data
Altman Z
0.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BNPJY buys
0
ABBV buys
0
No recent congressional trades found for BNPJY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBNPJYABBV
Forward yield6.37%3.06%
Annual dividend / share$0.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$25105.85M$102.3K
Annual income after 10y$24,370,393,261.15$24,771.77
Total dividends collected$25055.07M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BNPJY vs ABBV ($10,000, DRIP)

YearBNPJY PortfolioBNPJY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,973$1,273.13$11,550$430.00+$423.00BNPJY
2$15,660$2,849.21$13,472$627.96+$2.2KBNPJY
3$23,722$6,965.75$15,906$926.08+$7.8KBNPJY
4$45,106$19,722.82$19,071$1,382.55+$26.0KBNPJY
5$118,358$70,095.25$23,302$2,095.81+$95.1KBNPJY
6$470,440$343,796.57$29,150$3,237.93+$441.3KBNPJY
7$3,057,558$2,554,187.24$37,536$5,121.41+$3.02MBNPJY
8$34,300,696$31,029,108.98$50,079$8,338.38+$34.25MBNPJY
9$687,346,189$650,644,444.28$69,753$14,065.80+$687.28MBNPJY
10$25,105,853,684$24,370,393,261.15$102,337$24,771.77+$25105.75MBNPJY

BNPJY vs ABBV: Complete Analysis 2026

BNPJYStock

Banpu Public Company Limited engages in the coal mining and power businesses. It holds 50% interest in a 1,434 MW coal-fired power plant in Map Ta Phut Industrial Estate, Rayong Province, Thailand; and 100% interest in Temple 1 gas-fired power plant with a generation capacity of 768 MW located in Texas, the United States. The company also manages five coal mines in Kalimantan comprising Indominco, Jorong, Kitadin-Embalut, Trubaindo, and Bharinto, which produce a range of bituminous and sub-bituminous thermal coals in Indonesia. In addition, it operates the Gaohe coal mine in Shanxi Province and Hebi mine in Henan Province; operates and manages 3 coal-fired combined heat and power plants with a capacity of 539 megawatts in China; and owns various coal mines located in New South Wales, Australia. Further, the company operates various coal project in Mongolia; thermal power plants in Lao PDR; wind farm in Vietnam; and solar farms in Japan. Additionally, it provides solar rooftop solutions and installation for industries and large businesses; energy storage solutions; electric vehicle and fleet management services; consultation services on customized energy management system; and renewable energy ecosystem for clean energy. The company also involved in the power and steam production, purchase, and trading business; provident fund management; solar power generation; logistics; sales and marketing activities; natural gas business; investment in power and renewable energy; and research and development business. It also provides coal mining and trading; and business consultancy services, as well as fuel trading services. The company was formerly known as Ban Pu Coal Company Limited and changed its name to Banpu Public Company Limited in July 1993. Banpu Public Company Limited was founded in 1983 and is headquartered in Bangkok, Thailand.

Full BNPJY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BNPJY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BNPJY vs SCHDBNPJY vs JEPIBNPJY vs OBNPJY vs KOBNPJY vs MAINBNPJY vs JNJBNPJY vs MRKBNPJY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.